EASTERN COOPERATIVE ONCOLOGY GROUP

东方肿瘤合作组

• 批准号: 2414073
• 负责人: ARLENE ANN FORASTIERE
• 金额: $ 20.31万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1978
• 资助国家: 美国
• 起止时间: 1978-06-01 至 1999-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2414073
• 关键词: AIDS; AIDS related neoplasm /cancer; DNA topoisomerases; bone marrow transplantation; breast neoplasms; cancer prevention; central nervous system neoplasms; clinical trials; colon neoplasms; combination cancer therapy; combination chemotherapy; cooperative study; enzyme inhibitors; gene therapy; head /neck neoplasm; human subject; human therapy evaluation; lung neoplasms; lymphoma; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; paclitaxel; prostate neoplasms; reproductive system neoplasm; urinary tract neoplasms

Johns Hopkins has been a member of ECOG since 1955. Our primary goal is to bring innovative clinical research protocols and laboratory correlative studies piloted at Johns Hopkins to ECOG for further development. In conjunction with this, we provide leadership as protocol study chairs, disease and modality oriented committee chairs, as well as wide committee participation at the membership level. The specific aims during this grant renewal period are to: (1) continue to provide scientific leadership in the disease oriented committees: Lung, Head and Neck, Breast, Pathology and Pharmacology and to expand these efforts into AIDS and Neuro-Oncology; (2) to bring translational research, cell biology and molecular biology into clinical protocols for all stages of disease including prevention; (3) to expand our accrual and improve data management; (4) to increase participation of our affiliated community hospitals. We expect to achieve these aims through the successful efforts of our faculty in obtaining funded laboratory science and clinical research grants such as the SPORE grants in Lung and Prostate Cancer and our continuing Phase I Contract with the NCI. These grants will allow the development of phase I clinical trials, including bone marrow transplant, gene therapies, and novel cytotoxic agents, within Johns Hopkins that can then be taken to ECOG for disease-specific phase II and phase III evaluation. New areas of Johns Hopkins involvement include AIDS lymphoma and Neuro- Oncology. Mechanisms are in place to bring innovative research projects in these 2 areas into ECOG. Our accrual to studies and quality of data management will improve greatly. This will be accomplished through a total reorganization of our data management office with new administrative staff, a new ECOG dedicated research nurse, and a new senior data management coordinator. Accrual is expected to increase because of expanded clinical programs and faculty as we plan for a new larger Cancer Center at Johns Hopkins. In addition, a new director of Community Programs has been appointed with the specific goal of expanding our hospital network 'to provide greater access to high priority ECOG-NCI sponsored trials including cancer control and prevention studies.

约翰·霍普金斯大学自 1955 年以来一直是 ECOG 的成员。 目标是带来创新的临床研究方案和 约翰·霍普金斯大学向 ECOG 进行了实验室相关研究 进一步发展。与此相结合，我们提供 作为方案研究主席的领导力，以疾病和方式为导向 委员会主席以及委员会的广泛参与 会员级别。 本次赠款续展期间的具体目标是：(1) 继续在疾病导向方面提供科学领导 委员会：肺、头颈、乳腺、病理学和药理学 并将这些努力扩展到艾滋病和神经肿瘤学领域； (2) 至 带来转化研究、细胞生物学和分子生物学 纳入疾病各个阶段的临床方案，包括 预防; (3) 扩大我们的应计费用并改进数据管理； (4) 增加我们附属社区的参与 医院。 我们期望通过以下方面的成功努力实现这些目标 我们的教师获得资助的实验室科学和临床 研究资助，例如肺和前列腺领域的 SPORE 资助 癌症以及我们与 NCI 的持续第一阶段合同。这些 赠款将允许开展第一阶段临床试验， 包括骨髓移植、基因疗法和新疗法 约翰·霍普金斯大学内的细胞毒剂，然后可以被带到 ECOG 用于特定疾病的 II 期和 III 期评估。 新的 约翰·霍普金斯大学参与的领域包括艾滋病淋巴瘤和神经- 肿瘤学。建立创新研究机制 这两个领域的项目纳入ECOG。 我们的学习所得和 数据管理的质量将大大提高。这将是 通过彻底重组我们的数据管理来完成 办公室配备新的行政人员、新的 ECOG 专门研究人员 护士和新的高级数据管理协调员。应计是 由于临床项目的扩大和 我们计划在约翰霍普金斯大学建立一个更大的新癌症中心。 此外，还任命了一位新的社区项目总监 任命的具体目标是扩大我们的医院网络 '提供更多获得 ECOG-NCI 赞助的高优先级的机会 试验包括癌症控制和预防研究。